Weight Loss Emerges as Powerful Predictor of Lung Decline in Nintedanib Trials

For patients living with idiopathic pulmonary fibrosis, the number on the bathroom scale may matter far more than clinicians once believed. A comprehensive review published in Advances in Therapy has brought together published and previously unpublished trial data to examine how body weight, body mass index, and unintentional weight loss shape the course of fibrotic interstitial lung disease, and how these factors interact with nintedanib, one of the few antifibrotic therapies capable of slowing the relentless scarring that characterizes the condition. The analysis, led by an international team of pulmonologists and industry researchers, delivers a nuanced message: losing weight, particularly for patients who start treatment without obesity, is a harbinger of faster lung function decline, but it does not blunt the protective effect of the drug itself.

Fibrotic interstitial lung diseases comprise a diverse group of disorders that progressively destroy the delicate tissue of the lung parenchyma. Idiopathic pulmonary fibrosis, the archetypal member of this family, is almost always progressive, characterized by worsening breathlessness, a steady loss of lung capacity, and ultimately respiratory failure and death. Other interstitial lung diseases, including those driven by autoimmune conditions, hypersensitivity reactions, or occupational exposures, may also evolve into a progressive fibrotic phenotype, now termed progressive pulmonary fibrosis, which shares much of the grim natural history of idiopathic pulmonary fibrosis. Before the arrival of antifibrotic drugs, therapeutic options were limited, and median survival after diagnosis was measured in just a few years.

Weight loss and malnutrition have long been recognized as poor prognostic markers in chronic lung disease. In chronic obstructive pulmonary disease, for example, dietary supplementation in malnourished patients has been shown to improve exercise capacity, respiratory function, and health-related quality of life. The role of nutrition in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis has been far less well understood, in part because body weight in these patients can be influenced by many competing forces. Reduced exercise tolerance and corticosteroid use may push weight upward, while disease symptoms and medication side effects can suppress appetite and drive unintended loss. Studies vary widely in reported malnutrition prevalence, but a consistent finding has emerged across cohorts: unintentional weight loss is associated with worse outcomes.

The evidence is striking. Japanese and United Kingdom cohort studies in idiopathic pulmonary fibrosis demonstrated that an annual body weight loss of 6.1 percent predicted lower survival, even in patients in whom a decline in forced vital capacity, the standard measure of lung function, was not observed. A Danish survey of one hundred patients found that those reporting unintentional weight loss of at least five percent of body weight at baseline faced significantly higher risks of mortality and hospital admission within a year. In a multicentre study, both body mass index and weight loss were independently associated with one-year mortality in fibrotic interstitial lung disease. A meta-analysis of thirty-four studies encompassing more than eighteen thousand patients confirmed that low baseline body mass index and weight loss during the disease course were independent predictors of mortality.

To explore these relationships in the context of modern therapy, the review authors examined data from the pivotal Phase III trials of nintedanib. The INPULSIS program randomized 1,066 patients with idiopathic pulmonary fibrosis to nintedanib 150 mg twice daily or placebo, reporting annual rates of forced vital capacity decline of minus 239.9 milliliters and minus 207.3 milliliters in the placebo arms, which improved to minus 114.7 and minus 113.6 milliliters respectively with treatment. A pooled analysis demonstrated an overall reduction in the annual rate of decline of 109.9 milliliters with nintedanib. The INBUILD trial similarly randomized 663 patients with progressive fibrosing interstitial lung disease to the same treatment regimen. Crucially, both trials collected detailed data on baseline body mass index and weight change over fifty-two weeks, allowing investigators to stratify outcomes by nutritional status.

The findings from the placebo arms paint a consistent picture. Patients with lower body mass index, below 25 kilograms per square meter, experienced numerically greater annual decline in forced vital capacity than those in the mid-range of 25 to under 30 or the obese range of 30 and above. Likewise, patients who lost more than five percent of their body weight over the trial year declined faster than those who lost less or gained weight. Adverse associations extended to other endpoints as well, with lower baseline body mass index and unintended weight loss both linked to poorer outcomes overall. The new and previously unpublished analyses of pooled INPULSIS data added an important refinement: the deleterious effect of weight loss on lung function was most pronounced in patients who started with a body mass index below 25, was still evident in those in the overweight range who lost more than five percent of body weight, and was not observed at all in patients with obesity.

The relationship between weight loss, lung decline, and mortality proved complex rather than linear. In the INPULSIS placebo arm, patients losing more than five percent of body weight had numerically fewer deaths than those with lesser weight change, a finding the authors caution was based on exploratory analyses with limited events and was not powered for mortality comparisons. In INBUILD, by contrast, a four-kilogram weight decrease corresponded to an increased risk of acute exacerbation or death in multivariable analysis, though not to a greater risk of disease progression. These discordances likely reflect the multifactorial nature of mortality in fibrotic lung disease, differences in baseline characteristics between populations, and the fact that forced vital capacity decline and death capture related but distinct dimensions of disease severity.

A central question hovered over the entire analysis: because nintedanib itself commonly causes gastrointestinal side effects, including diarrhoea, nausea, and appetite loss, could treatment-induced weight loss undermine the drug’s benefits? The data emphatically answer no. Weight loss exceeding five percent over fifty-two weeks occurred in 37.8 percent of nintedanib-treated patients in INPULSIS compared with 20.1 percent on placebo, and in 55 percent of nintedanib patients in INBUILD versus 39 percent on placebo. Yet in the nintedanib arms, the rate of forced vital capacity decline was similar between patients with and without significant weight loss, at roughly 103 versus 121 milliliters per year, and the treatment effect versus placebo was preserved across every body mass index subgroup. Indeed, the greatest benefit was observed in patients with lower body mass index and those experiencing weight loss, suggesting the antifibrotic effect operates independently of nutritional status.

The review also situates these findings within a broader body composition literature that moves beyond simple scales. Body mass index cannot distinguish fat mass from lean mass, and recent work indicates that lung function in fibrotic disease correlates with muscle quantity and quality, with sarcopenia associated with poor prognosis. Fat-free mass index has been significantly correlated with survival in idiopathic pulmonary fibrosis, the Geriatric Nutritional Risk Index predicts both prognosis and antifibrotic continuation rates, and bioimpedance-derived phase angle outperformed traditional measures in discriminating patients with worse lung function and quality of life. Measures of skeletal muscle attenuation have been associated with lung function and functional capacity, underscoring that not all weight loss carries the same physiological meaning.

The authors conclude that nutritional advice and weight monitoring should form an integral component of supportive care, with targeted strategies aimed at patients at highest risk, particularly those with low baseline body mass index who subsequently lose weight. Practical recommendations include increasing protein intake, eating smaller and more frequent meals to counteract appetite loss, and maintaining hydration to manage gastrointestinal toxicities, while adherence to a Mediterranean diet has been associated with improved lung function in related populations. A recent pilot randomized controlled trial demonstrated that specialist dietary intervention is feasible in patients experiencing unintentional weight loss, though definitive evidence that nutrition directly modifies long-term outcomes remains limited. Most importantly, the findings reinforce a message for patients and clinicians alike: rather than discontinuing antifibrotic therapy when gastrointestinal effects and weight loss emerge, every effort should be made to manage these side effects and maintain adherence, because the preservation of lung function that these drugs deliver outweighs the metabolic cost, and the antifibrotic shield holds firm regardless of what the scale says.

Subject of Research: The impact of weight loss and body mass index on outcomes in nintedanib clinical trials for interstitial lung disease.

Article Title: Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease

Article References: Kreuter, M., Kottmann, R. M., Luo, F., Coeck, C., Kanakapura, M., Schlecker, C., Ritter, I., & Handa, T. (2026). Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease. Advances in Therapy. https://doi.org/10.1007/s12325-026-03785-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03785-z

Keywords: nintedanib, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, weight loss, body mass index, interstitial lung disease, forced vital capacity, antifibrotic therapy, malnutrition, nutrition, INPULSIS, INBUILD